Clinical experience with saralasin infusion in hypertensive patients.
Renal arteriography gives a reliable anatomic delineation of the renal vasculature. However, the presence of renal arterial disease does not determine the physiologic significance of the lesion. The intravenous  infusion of saralasin, a specific angiotensin II antagonist, has been investigated as a method for identifying patients with hypertension dependent upon excessive angiotensin II activity. Correlations between the blood pressure response to saralasin infusion, peripheral and differential renal vein plasma renin levels and renal angiography have been obtained in 35 hypertensive patients. The results suggest that a hypotensive response to saralasin infusion provides an adjunct to renin determinations for recognizing angiotensinogenic renovascular hypertension. However, false negative responses to saralasin occur. The reasons for these negative responses need to be determined before saralasin infusion can be employed as the sole screening test for renovascular hypertension.
D000328:Adult; D000368:Aged; D000804:Angiotensin II / Q000031:analogs & derivatives*; D005260:Female; D006801:Humans; D006973:Hypertension / Q000175:diagnosis*; D006977:Hypertension, Renal / Q000175:diagnosis*; D007275:Injections, Intravenous; D008297:Male; D008875:Middle Aged; D012078:Renal Artery Obstruction / Q000175:diagnosis; D012504:Saralasin / Q000008:administration & dosage
D000804:Angiotensin II; D012504:Saralasin